- Home
- ROL vs BIIB Comparison
ROL vs BIIB Comparison
Compare ROL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROL
- BIIB
- Stock Information
- Founded
- ROL 1948
- BIIB 1978
- Country
- ROL United States
- BIIB United States
- Employees
- ROL N/A
- BIIB N/A
- Industry
- ROL Diversified Commercial Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ROL Finance
- BIIB Health Care
- Exchange
- ROL Nasdaq
- BIIB Nasdaq
- Market Cap
- ROL 23.9B
- BIIB 25.1B
- IPO Year
- ROL N/A
- BIIB 1991
- Fundamental
- Price
- ROL $46.60
- BIIB $149.02
- Analyst Decision
- ROL Buy
- BIIB Buy
- Analyst Count
- ROL 6
- BIIB 26
- Target Price
- ROL $51.00
- BIIB $248.00
- AVG Volume (30 Days)
- ROL 1.7M
- BIIB 1.6M
- Earning Date
- ROL 02-12-2025
- BIIB 02-11-2025
- Dividend Yield
- ROL 1.42%
- BIIB N/A
- EPS Growth
- ROL 16.84
- BIIB 10.05
- EPS
- ROL 0.97
- BIIB 11.06
- Revenue
- ROL $3,310,625,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- ROL $10.99
- BIIB N/A
- Revenue Next Year
- ROL $8.38
- BIIB N/A
- P/E Ratio
- ROL $48.05
- BIIB $13.47
- Revenue Growth
- ROL 11.07
- BIIB N/A
- 52 Week Low
- ROL $40.41
- BIIB $145.07
- 52 Week High
- ROL $52.16
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- ROL 30.04
- BIIB 32.44
- Support Level
- ROL $46.18
- BIIB $145.07
- Resistance Level
- ROL $49.69
- BIIB $149.92
- Average True Range (ATR)
- ROL 0.77
- BIIB 3.81
- MACD
- ROL -0.30
- BIIB 0.05
- Stochastic Oscillator
- ROL 11.70
- BIIB 22.51
About ROL Rollins Inc.
Rollins is a global leader in route-based pest-control services, with operations spanning North, Central and South America, Europe, the Middle East and Africa and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, market leader in the US, where it boasts near national coverage, and in Canada. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on US and Canadian markets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.